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We report acute encephalopathy associated with inﬂ  u-
enza A infection in 3 adults. We detected high cerebrospinal 
ﬂ  uid (CSF) and plasma concentrations of CXCL8/IL-8 and 
CCL2/MCP-1 (CSF/plasma ratios >3), and interleukin-6, 
CXCL10/IP-10, but no evidence of viral neuroinvasion. Pa-
tients recovered without sequelae. Hyperactivated cytokine 
response may play a role in pathogenesis.
I
nﬂ  uenza-associated acute encephalopathy has been de-
scribed in children, and results in a high frequency of 
neurologic sequelae and death. Altered consciousness, dis-
orientation, and seizures occur within a few days after the 
onset of fever and respiratory symptoms (1–3). In some 
patients, symptoms are transient but in others rapid pro-
gression to necrotizing encephalitis, deep coma, and death 
may occur (1–3). Cases in adults are infrequently reported 
and remain poorly characterized, although the more com-
plex clinical scenarios in adults may have hindered case 
recognition (1,4–6). The pathogenesis is unclear, but a hy-
peractivated cytokine response, rather than viral invasion, 
is believed responsible in most childhood cases (1–5). We 
describe 3 cases of acute encephalopathy associated with 
inﬂ  uenza A infection in adults. The clinical, virologic, im-
munologic ﬁ  ndings (cytokines in plasma and cerebrospinal 
ﬂ  uid [CSF]), and CSF penetration of oseltamivir for these 
cases are reported.
The Study
At Prince of Wales Hospital, Hong Kong (7), from 
January 2007 through August 2008, inﬂ  uenza infection 
was diagnosed for >460 hospitalized adult patients for 
whom acute febrile respiratory illnesses had been diag-
nosed. Nasopharyngeal aspiration and immunoﬂ  uores-
cence assays (IFA) were used for rapid diagnosis of in-
ﬂ  uenza A and B infection, conﬁ  rmed by virus isolation. 
Thirteen (2.8%) patients had signs of confusion or altered 
consciousness, together with fever and respiratory symp-
toms (mean ± SD age 77.7 ± 8.8 years). We studied 3 
patients from whom CSF was obtained for analysis, and 
who fulﬁ  lled the deﬁ  nition of inﬂ  uenza-associated acute 
encephalopathy (altered mental status >24 hours within 5 
days of inﬂ  uenza onset and without alternative explana-
tion) (1,2,4–6).
Nasopharyngeal aspirates were subjected to IFA, virus 
isolation, and subsequent subtyping (7). CSF specimens 
were subjected to virus isolation using MDCK cells, and 
reverse transcription–PCR to detect inﬂ  uenza virus RNA 
by using H1/H3 subtype-speciﬁ  c primers. Herpes simplex 
virus, herpes zoster virus, and enterovirus DNA/RNA was 
detected using PCRs (online Technical Appendix, available 
from www.cdc.gov/EID/content/16/1/139-Techapp.pdf).
CSF and plasma samples collected on the same day 
were analyzed simultaneously for the concentrations of 11 
cytokines/chemokines by bead-based multiplex ﬂ  ow cytom-
etry. Their assay methods and plasma reference ranges (es-
tablished from >100 healthy persons) have been described 
(online Technical Appendix) (7). In CSF, in patients with-
out central nervous system (CNS) disease/infection, cytok-
ines/chemokines are either undetectable (e.g., interleukin-6 
[IL-6], CXCL8/IL-8, CXCL10/IP-10, CXCL9/MIG) or 
present at low levels (e.g., CCL2/MCP-1) (8–10).
Concentrations of oseltamivir phosphate (OP) and 
its biologically active metabolite oseltamivir carboxylate 
(OC) were measured in CSF and plasma taken simultane-
ously from 1 patient who received concurrent treatment, 
using tandem mass spectrometry (11). The assay methods 
have been described (online Technical Appendix).
The clinical and virologic ﬁ  ndings are summarized 
in Table 1. All case-patients were elderly (72–86 years of 
age), but none were known to have neuropsychiatric ill-
ness, dementia, or to be taking psychotropic medication. 
None had received updated inﬂ  uenza vaccination (6). Con-
fusion and altered consciousness developed in patients 1 
and 2 one to 2 days after the onset of fever and cough. 
These patients had no meningismus, focal neurologic def-
icit, hypotension, respiratory distress, or metabolic distur-
bances. Brain computed tomography (CT) scans showed 
no acute cerebral lesion. CSF analyses showed no bacteri-
al or viral pathogen or pleocytosis. Oseltamivir was given 
to patient 2 only when inﬂ  uenza A was later conﬁ  rmed 
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antiviral treatment. Both patients recovered in the next 2 
days. Patient 3 had fever, severe chronic obstructive pul-
monary disease exacerbation requiring noninvasive venti-
latory support, complicated by acute coronary syndrome. 
He was given oseltamivir, 75 mg 2×/day, after inﬂ  uenza 
A infection was conﬁ  rmed. Agitation and confusion de-
veloped in the patient on day 3–4 of illness (onset after 
the third dose of oseltamivir), despite resolution of the pa-
tient’s respiratory failure. These symptoms were followed 
by involuntary, tremulous movements involving all 4 
limbs, while at rest and during movement. Brain CT scan 
was normal. Electroencephalogram showed generalized 
slowing. Oseltamivir was stopped after the ninth dose, but 
tremor persisted. CSF analyses showed no pathogen or 
pleocytosis. The patient’s symptoms resolved in the next 
3–4 days without sequelae.
Despite apparently normal CSF ﬁ  ndings, high concen-
trations of cytokines/chemokines were detected in the CSF 
and plasma specimens of all patients (Table 2). Plasma con-
centrations of IL-6, CXCL8/IL-8, CXCL10/IP-10, CCL2/
MCP-1, and CXCL9/MIG were elevated at median values 
of 2.0, 2.8, 11.9, 3.7, and 2.1× the upper limits of their re-
spective reference ranges (comparable to or higher than that 
observed in other hospitalized inﬂ  uenza patients) (Table 2) 
(7). Other cytokines were not elevated (4,7). In their CSF, 
IL-6, CXCL8/IL-8, CXCL10/IP-10, and CCL2/MCP-1 were 
consistently detected, and were elevated at median values of 
2.6, 15.0, 3.4, and 20.0 × the upper limits of their respective 
plasma reference ranges. The CSF/plasma concentration 
ratios of CXCL8/IL-8 and CCL2/MCP-1 were >3 (median 
CSF/plasma ratio 5.4 and 8.0, respectively).
Simultaneous CSF and plasma OC and OP concen-
trations were determined for patient 3, as symptoms pro-
gressed at 18 h  after oseltamivir. The concentrations (mean 
± SD) of OC in duplicate CSF and plasma samples were 
18.3 ± 0.9 ng/mL and 143.8 ± 3.3 ng/mL, respectively; the 
CSF/plasma concentration ratio was 12%–13%. The OP 
plasma concentration was 1.05 ± 0.03 ng/mL; it was not 
detectable in the CSF.
Conclusions
We report 3 adults with acute encephalopathy (altered 
consciousness, confusion) associated with inﬂ  uenza. High 
CSF and blood cytokine/chemokine (CXCL8/IL-8, CCL2/
MCP-1, IL-6, CXCL10/IP-10) levels were detected. No ev-
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Table 1. Clinical and laboratory findings in 3 patients with acute encephalopathy associated with influenza infection, Prince of Wales 
Hospital, Hong Kong* 
Clinical and laboratory findings  Patient 1  Patient 2  Patient 3 
Age, y/sex  76/M 86/F 72/M
Concurrent illnesses  Ischemic heart disease Diabetes mellitus, hypertension  COPD 
Influenza vaccination within 6 mo  None None None
Symptoms on examination  Fever >38qC, cough, 
disorientation, incoherent 
speech, mental dullness 
Fever >38qC, cough, delirious, 
impaired consciousness, did not 
follow verbal command 
Fever >38qC, cough, 
disorientation, agitation, 
incoherent speech, 
involuntary 4-limb tremor 
Focal neurologic sign or meningism  Absent Absent Absent
Chest radiograph, consolidation Absent Absent Absent
Antiviral (oseltamvir)  None Given Given
Outcome (duration of encephalopathy)  Recovered (2–3 d)  Recovered (3–4 d)  Recovered (6–7 d) 
Brain CT scan (noncontrast)  Normal Old ischemic changes; known 
small, calcified meningioma 
Normal
Virus isolated from NPA  Seasonal (H1N1) 2008  Subtype H3N2  Subtype H3N2 
CSF testing results 
  Opening pressure, cm H2O1 1 9 1 4
  Cell count (x 10
6/L) 1 – 0
 Glucose,  mmol/L  4.2 7.4 3.7
 Protein,  g/L  0.46 0.47 0.16
 Virus  isolated  None None None
  RT-PCR for H3 and H1 influenza virus  Negative Negative Negative
 Bacterial  culture  Negative Negative Negative
  Others  HSV, HZV, and 
enterovirus PCR 
negative
HSV, HZV, and enterovirus 
PCR negative 
HSV PCR negative 
*COPD, chronic obstructive pulmonary disease; CT, computed tomographic scan; NPA, nasopharyngeal aspirate; CSF, cerebrospinal fluid; RT-PCR, 
reverse transcription–PCR; HSV, herpes simples virus; HZV, herpes zoster virus. In all cases, there was no hypoglycemia, and liver and renal function 
test results were normal. C-reactive protein level was elevated in all cases. For patient 3, an electroencephalogram was performed and showed 
generalized slowing of background consistent with moderate encephalopathic change (similar to that observed in septic encephalopathy) (1,6). Findings 
are consistent with previous reports on adult cases of influenza-associated encephalopathy: patients are all unvaccinated, pleocytosis and cerebral 
imaging abnormalities (even with magnetic resonance imaging) are usually absent, and symptoms are generally self-limiting (1,6). Most reports have 
mentioned influenza A as a cause of encephalopathy, and more commonly subtype H3N2 (1–6). Encephalopathy and Inﬂ  uenza A Infection in Adults
idence of direct viral neuroinvasion was found. All patients 
recovered rapidly without sequelae (1,6).
Our ﬁ  ndings agree with studies of inﬂ  uenza-associated 
encephalopathy in children. Inﬂ  uenza virus is rarely de-
tected in the CSF, and pleocytosis is often absent (1,2,4–6). 
High levels of cytokines (e.g., IL-6, soluble tumor necrosis 
factor receptor 1) can be consistently found in CSF/blood 
specimens, correlating with disease severity and outcomes 
(hyperactivated cytokine response is absent in febrile sei-
zure associated with inﬂ  uenza) (2–4,8). We found a broad-
er range of cytokines/chemokines being activated (7); for 
certain cytokines (CXCL8/IL-8, CCL2/MCP-1), the CSF 
concentrations were 3× those in plasma. IL-6, CXCL8/
IL-8, CCL2/MCP-1 and CXCL10/IP-10 have been shown 
to play pathogenic roles in CNS viral infections, cerebral 
injury, and acute brain syndrome in susceptible patients 
(7,9,10,12). The high CSF/plasma ratios suggest that for 
some cytokines, activation within the CNS might have oc-
curred along with respiratory-tract and systemic produc-
tions (cytokines are not detected in CSF normally; (Table 2) 
(4,7–10,12). Resident macrophages/monocytes, astrocytes, 
microglial and endothelial cells in the CNS are shown to 
release cytokines/chemokines when stimulated by viral/
inﬂ  uenza infection; activation mechanisms without involv-
ing overt CNS invasion have been suggested (1,4,9,12–14). 
Cytokines may cause direct neurotoxic effects, cerebral me-
tabolism changes, or breakdown of the blood-brain-barrier 
(endothelial injury) to produce symptoms (1–4,8,12–14). 
Whether early viral suppression by antivirals can lead to at-
tenuation of these cytokine responses and better outcomes 
warrants further study (7).
We measured oseltamivir concentrations because of 
the concerns over its neuropsychiatric side-effects in chil-
dren and adolescents. However, only the active metabolite 
(OC) was detected in the CSF of patient 3; the CSF/plasma 
concentration ratio was 12%–13% (18.3/143.8 ng/mL) at 
18-hours postdose. This degree of CSF penetration is simi-
lar to that observed among healthy patients, with a Cmax 
CSF/plasma concentration ratio of 3.5% (at ≈8 hours), and 
a ratio of ≈10% at 18 hours (concentration-time proﬁ  les 
for plasma/CSF differ). Assuming a similar ratio, the CSF 
OP concentration would have fallen below the assay’s de-
tection limit (0.25 ng/mL) by 18 hours (11,15). The low 
CSF drug-penetration, together with high cytokines in CSF 
and symptom progression despite drug withdrawal suggest 
that the manifestations of patient 3 may have been disease-
related. Symptoms developed in patients 1 and 2 without 
antiviral exposure. Further investigations on the CNS ef-
fects of oseltamivir in the clinical setting are needed..
Our study is limited by the small patient number and 
the lack of feasibility in obtaining CSF for study/compari-
son in inﬂ  uenza patients without neurologic symptoms. 
Further studies on the clinical spectrum of inﬂ  uenza en-
cephalopathy and encephalitis in adults (1,6) and their 
pathogenesis are indicated. In conclusion, acute enceph-
alopathy may occur in adults with inﬂ  uenza. Exuberant 
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Table 2. Cytokine and chemokine concentrations in CSF and plasma samples from 3 patients with acute encephalopathy associated 
with influenza A infection, Prince of Wales Hospital, Hong Kong* 
CSF/plasma cytokine concentration, pg/mL (ratio) 
Cytokine or chemokine  Reference range, pg/mL  Patient 1  Patient 2  Patient 3 
IL-6†  <3.1  8.0/6.3 (1.3)  11.6/35.1 (0.3)  2.2/5.9 (0.4) 
CXCL8/IL-8‡  <5.0  84.0/15.5 (5.4)  74.8/13.8 (5.4)  21.9/6.3 (3.5) 
CXCL10/IP-10†  202–1,480  15,374/102,019 (0.2)  5,101/17,594 (0.3)  1,371/1,550 (0.9) 
CCL2/MCP-1‡  < 10-57  996/82 (12.1)  1,287/336 (3.8)  – 
CXCL9/MIG  48–482  11,58/14,001 (0.1)  70/333 (0.2)  145/1,019 (0.1) 
IFN-J  <15.6 UD/14.4  4.7/10.1  0.4/2.0 
IL-12p70 <7.8  1.5/UD  1.3/UD  UD/UD 
TNF-D  <10.0 1.7/1.4  UD/1.2  UD/UD 
IL-10 <7.8  2.5/2.2  UD/7.3  UD/1.7 
IL-1E  <3.9 UD/UD  UD/3.7  UD/UD 
CCL5/RANTES 4,382–18,783  4/2,507  14/1,609  1.3/814 
*CSF, cerebrospinal fluid; –, test not done due to inadequate sample; UD, undetectable (i.e., below the detection limit of the cytokine/chemokine assay). 
Cytokines: Interleukin (IL)–1ȕ, IL-6, IL-10, IL-12p70, tumor necrosis factor Į (TNF-Į). Chemokines: CXCL8/IL-8, monokine induced by interferon-Ȗ (IFN- 
Ȗ) (CXCL9/MIG), IFN-Ȗ–inducible protein-10 (CXCL10/IP-10), monocyte chemoattractant protein–1 (CCL2/MCP-1), and regulated upon activation normal 
T cell–expressed and secreted (CCL5/RANTES). The plasma reference ranges are established from >100 healthy adults. The assay sensitivities of IL-1ȕ, 
IL-6, IL-10, IL-12p70, TNF-Į, IL8, MIG, IP-10, MCP-1, RANTES, and IFN-Ȗ are 2.5, 3.3, 3.7, 1.9, 7.2, 0.2, 2.5, 2.8, 2.7, 1.0, and 7.1 pg/mL, respectively. 
Coefficients of variation are all <10%. In an earlier study involving 39 adult influenza patients hospitalized with cardio-respiratory complications (7), the 
median (interquartile range) plasma concentrations of IL-6, IL-8, IP-10, MCP-1, and MIG were 10.6 (4.2–18.4), 5.4 (2.5–8.7), 7,043.0 (4,025.1–1,2381.1), 
76.5 (49.5-97.0), and 992.1 (499.1–1,992.3) pg/mL, respectively. In CSF, in subjects without neurologic disease/infection, these cytokines/chemokines 
are either undetectable or present at low levels (8–10). In a pediatrics influenza cohort, CSF cytokine levels were substantially higher in encephalopathy 
cases when compared to those with febrile seizure; CSF/plasma concentration was <1 (8).  
†CSF cytokine concentrations above plasma reference ranges. 
‡CSF/plasma cytokine concentration ratio consistently >3 (3.5–12.1), in addition to CSF cytokine concentrations being above the plasma reference 
ranges. For IFN-Ȗ, IL-12p70, TNF-Į, IL-10, IL-1ȕ and RANTES, because of their low/undetectable levels, the CSF/plasma ratios were not calculated. CSF 
specimens from patients 1 and 2 were collected at the peak of symptoms, and before antiviral treatment (if given); CSF from patient 3 was collected when 
persistent tremor developed 18 hours after the ninth dose of oseltamivir; the drug was stopped afterward. cytokine/chemokine response may play an important role 
in its pathogenesis.
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